Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
LUSEDRA is an intravenous small-molecule solution approved in 2008 for interstitial cystitis, a chronic bladder condition characterized by bladder pain and urinary frequency. The mechanism of action is not publicly disclosed in available data. It represents a specialized treatment option in a limited patient population.
Product is approaching loss of exclusivity with limited market opportunity; teams are likely focused on lifecycle extension or transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia
Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery
A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion
A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure
A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations
Worked on LUSEDRA at Eisai? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LUSEDRA offers limited career growth potential due to its niche market, approaching LOE, and lack of linked job postings. Roles available are primarily defensive, focused on managing decline and protecting market share against generics rather than expansion or innovation.